by MM360 Staff | Apr 30, 2025 | Uncategorized
Source: CureToday articles A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia. Read More
by MM360 Staff | Apr 29, 2025 | Uncategorized
Source: CureToday articles The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer. Read More
by MM360 Staff | Apr 29, 2025 | Uncategorized
Source: CureToday articles Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer. Read More
by MM360 Staff | Apr 29, 2025 | Uncategorized
Source: CureToday articles TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study. Read More
by MM360 Staff | Apr 29, 2025 | Uncategorized
Source: CureToday articles A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time. Read More
by MM360 Staff | Apr 29, 2025 | Uncategorized
Source: CureToday articles The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers. Read More
